Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas.

作者: J H Edmonson , L M Ryan , R H Blum , J S Brooks , M Shiraki

DOI: 10.1200/JCO.1993.11.7.1269

关键词: Survival analysisDoxorubicinSarcomaChemotherapyToxicityCisplatinSurgeryUrologyIfosfamideMedicineRandomization

摘要: PURPOSEThis three-armed phase III study in adults with advanced soft tissue sarcomas was planned as a comparison of objective regression rates, toxicity, and survival patients receiving doxorubicin alone, ifosfamide plus doxorubicin, mitomycin cisplatin.PATIENTS AND METHODSBetween December 1987 July 1990, 279 histologically confirmed were enrolled to receive treatment A (doxorubicin 80 mg/m2), B (ifosfamide 7.5 g/m2 60 or C (mitomycin 8 mg/m2 40 cisplatin mg/m2).RESULTSOf 262 assessable patients, 74 (29%) achieved tumor regression. Objective occurred 20% the 90 who received alone (complete remission [CR] rate, 2%), 34% 88 (CR 3%), 32% 84 7%). With grade 3 greater myelosuppression 53% gr...

参考文章(24)
Karen Antman, John Crowley, Stanley P Balcerzak, Saul E Rivkin, Geoffrey R Weiss, Anthony Elias, Ronald B Natale, Robert M Cooper, Bart Barlogie, Donald L Trump, None, An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. Journal of Clinical Oncology. ,vol. 11, pp. 1276- 1285 ,(1993) , 10.1200/JCO.1993.11.7.1276
E C Borden, D A Amato, C Rosenbaum, H T Enterline, M J Shiraki, R H Creech, H J Lerner, P P Carbone, Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas. Journal of Clinical Oncology. ,vol. 5, pp. 840- 850 ,(1987) , 10.1200/JCO.1987.5.6.840
Friedrich Kallinowski, Paul Okunieff, Peter Vaupel, Blood Flow, Oxygen and Nutrient Supply, and Metabolic Microenvironment of Human Tumors: A Review Cancer Research. ,vol. 49, pp. 6449- 6465 ,(1989)
Sara Rockwell, Katherine A. Kennedy, Alan C. Sartorelli, Mitomycin-C as a prototype bioreductive alkylating agent: In vitro studies of metabolism and cytotoxicity International Journal of Radiation Oncology Biology Physics. ,vol. 8, pp. 753- 755 ,(1982) , 10.1016/0360-3016(82)90728-3
R. E. Wilson, P. C. Keng, R. M. Sutherland, Drug Resistance in Chinese Hamster Ovary Cells During Recovery From Severe Hypoxia Journal of the National Cancer Institute. ,vol. 81, pp. 1235- 1240 ,(1989) , 10.1093/JNCI/81.16.1235
Stuart J. Pocock, Richard Simon, Sequential Treatment Assignment with Balancing for Prognostic Factors in the Controlled Clinical Trial Biometrics. ,vol. 31, pp. 103- 115 ,(1975) , 10.2307/2529712
Beverly A. Teicher, Terence S. Herman, Lawrence Shulman, Glenn Bubley, C. Norman Coleman, Emil Frei, Combination of etanidazole with cyclophosphamide and platinum complexes Cancer Chemotherapy and Pharmacology. ,vol. 28, pp. 153- 158 ,(1991) , 10.1007/BF00685502
Robert M. O'Bryan, James K. Luce, Robert W. Talley, Jeffrey A. Gottlieb, Laurence H. Baker, Gianni Bonadonna, Phase II evaluation of adriamycin in human neoplasia Cancer. ,vol. 32, pp. 1- 8 ,(1973) , 10.1002/1097-0142(197307)32:1<1::AID-CNCR2820320101>3.0.CO;2-X
Janine L. Mansi, Cyril Fisher, Eve Wiltshaw, Sheila Macmillan, Michael King, Robin Stuart-Harris, A phase I-II study of ifosfamide in combination with adriamycin in the treatment of adult soft tissue sarcoma. European Journal of Cancer and Clinical Oncology. ,vol. 24, pp. 1439- 1443 ,(1988) , 10.1016/0277-5379(88)90334-3
BrianM.J. Cantwell, James Carmichael, Sarah Ghani, AdrianL. Harris, A phase II study of ifosfamide/mesna with doxorubicin for adult soft tissue sarcoma Cancer Chemotherapy and Pharmacology. ,vol. 21, pp. 49- 52 ,(1988) , 10.1007/BF00262738